drugset / Trial / NCT01049165

Single Ascending Dose (BMS-813160) Study

NCT01049165

Phase 1 Completed 70 enrolled Bristol-Myers Squibb
RandomizedParallel-groupTriple-blindBasic science

Summary

The primary purpose of this study is to evaluate the safety and tolerability of single oral doses of BMS-813160 in healthy subjects

Timeline

Start
2010-02
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator BMS-813160 Small molecule 5 mg Oral
Comparator BMS-813160 Small molecule 20 mg Oral
Comparator BMS-813160 Small molecule 60 mg Oral
Comparator BMS-813160 Small molecule 150 mg Oral
Comparator BMS-813160 Small molecule 300 mg Oral
Comparator BMS-813160 Small molecule 600 mg Oral
Comparator BMS-813160 Small molecule 1200 mg Oral
Comparator BMS-813160 Small molecule 2000 mg Oral

Indications

No indication recorded.